Book contents
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part 1.1 Analytical techniques: analysis of DNA
- Part 1.2 Analytical techniques: analysis of RNA
- Part 2.1 Molecular pathways underlying carcinogenesis: signal transduction
- Part 2.2 Molecular pathways underlying carcinogenesis: apoptosis
- Part 2.3 Molecular pathways underlying carcinogenesis: nuclear receptors
- Part 2.4 Molecular pathways underlying carcinogenesis: DNA repair
- Part 2.5 Molecular pathways underlying carcinogenesis: cell cycle
- Part 2.6 Molecular pathways underlying carcinogenesis: other pathways
- Part 3.1 Molecular pathology: carcinomas
- Part 3.2 Molecular pathology: cancers of the nervous system
- Part 3.3 Molecular pathology: cancers of the skin
- Part 3.4 Molecular pathology: endocrine cancers
- Part 3.5 Molecular pathology: adult sarcomas
- Part 3.6 Molecular pathology: lymphoma and leukemia
- Part 3.7 Molecular pathology: pediatric solid tumors
- Part 4 Pharmacologic targeting of oncogenic pathways
- 78 Oncology drug discovery for biologics: antibody development strategies and considerations
- 79 Targeting the EGFR family of receptor tyrosine kinases
- 80 Therapeutic approaches with antibodies to cell-surface receptors
- 81 Signal transduction in tumor angiogenesis
- 82 Tyrosine-kinase inhibitors in oncology
- 83 Anti-estrogens and selective estrogen-receptor modulators
- 84 Therapeutic applications of anti-sense mechanisms for the treatment of cancer
- 85 Induction of apoptosis
- 86 DNA-methylation inhibitors
- 87 Histone deacetylase inhibitors
- 88 Drug resistance: as complex and diverse as the disease itself
- 89 Molecular profiling and therapeutic decision-making: the promise of personalized medicine
- 90 DNA repair inhibition in anti-cancer therapeutics
- Index
- References
89 - Molecular profiling and therapeutic decision-making: the promise of personalized medicine
from Part 4 - Pharmacologic targeting of oncogenic pathways
Published online by Cambridge University Press: 05 February 2015
Book contents
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part 1.1 Analytical techniques: analysis of DNA
- Part 1.2 Analytical techniques: analysis of RNA
- Part 2.1 Molecular pathways underlying carcinogenesis: signal transduction
- Part 2.2 Molecular pathways underlying carcinogenesis: apoptosis
- Part 2.3 Molecular pathways underlying carcinogenesis: nuclear receptors
- Part 2.4 Molecular pathways underlying carcinogenesis: DNA repair
- Part 2.5 Molecular pathways underlying carcinogenesis: cell cycle
- Part 2.6 Molecular pathways underlying carcinogenesis: other pathways
- Part 3.1 Molecular pathology: carcinomas
- Part 3.2 Molecular pathology: cancers of the nervous system
- Part 3.3 Molecular pathology: cancers of the skin
- Part 3.4 Molecular pathology: endocrine cancers
- Part 3.5 Molecular pathology: adult sarcomas
- Part 3.6 Molecular pathology: lymphoma and leukemia
- Part 3.7 Molecular pathology: pediatric solid tumors
- Part 4 Pharmacologic targeting of oncogenic pathways
- 78 Oncology drug discovery for biologics: antibody development strategies and considerations
- 79 Targeting the EGFR family of receptor tyrosine kinases
- 80 Therapeutic approaches with antibodies to cell-surface receptors
- 81 Signal transduction in tumor angiogenesis
- 82 Tyrosine-kinase inhibitors in oncology
- 83 Anti-estrogens and selective estrogen-receptor modulators
- 84 Therapeutic applications of anti-sense mechanisms for the treatment of cancer
- 85 Induction of apoptosis
- 86 DNA-methylation inhibitors
- 87 Histone deacetylase inhibitors
- 88 Drug resistance: as complex and diverse as the disease itself
- 89 Molecular profiling and therapeutic decision-making: the promise of personalized medicine
- 90 DNA repair inhibition in anti-cancer therapeutics
- Index
- References
Summary
Since the development of microarray technologies, there has been significant investment in the potential for gene-expression profiling to drive innovation in clinical diagnostics and therapy. Now, twenty years since the first prototype was developed, we assess the impact on clinical management of cancer patients through new diagnostic tools and treatment strategies developed as a result of this technology, and present a perspective to both the limitations and future promise of molecular profiling in the clinic.
The beginnings of the microarray revolution
The origins of DNA microarray technology date back to the late 1980s, when Stephen P.A. Fodor pioneered the first microarray system, the Affymetrix GeneChip® (Figure 89.1; 1). With Affymetrix commencing commercial sales of the GeneChip® system for research use in 1994, and the publication in 1995 by Patrick Brown and colleagues at Stanford University assessing gene expression in Arabidopsis thaliana, the research landscape was changed irrevocably (2). While Affymetrix continued to dominate the field, the Human Genome Initiative provided the impetus for researchers to actively pursue development of alternative types of DNA microarrays, with many other platforms entering the arena (3). By the mid-1990s, microarray technology had moved from a boutique technology to an integral component of the medical research toolbox and was responsible for attracting major investment into the biotechnology and pharmaceutical sector with the focus firmly on understanding the molecular basis of human disease and informing treatment decisions.
- Type
- Chapter
- Information
- Molecular OncologyCauses of Cancer and Targets for Treatment, pp. 929 - 935Publisher: Cambridge University PressPrint publication year: 2013
References
, , , et al. Light-directed, spatially addressable parallel chemical synthesis. Science 1991;251:767–73.CrossRef
, , , Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467–70.CrossRef
, Navigating gene expression using microarrays–a technology review. Nature Cell Biology 2001;3:E190–5.
, , , et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531–7.CrossRef
, , , et al. Molecular portraits of human breast tumours. Nature 2000;406:747–52.CrossRef
Draft Guidance for Industry, Clinical Laboratories, and FDA Staff, In vitro diagnostic multivariate index assays. Rockville, MD: US Department of Health and Human Services, FDA;2007.
, Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nature Reviews Cancer 2007;7:545–53.
, Gene-expression signatures in breast cancer. New England Journal of Medicine 2009;360:790–800.CrossRefGoogle ScholarPubMed
, , , et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 2004;351:2817–26.CrossRefGoogle ScholarPubMed
, , , et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–6.CrossRef
, , , et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671–9.CrossRef
, , , et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology 2006;24:3726–34.CrossRefGoogle ScholarPubMed
, , , et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology 2007;25:5287–312.CrossRefGoogle Scholar
Getting the noise out of gene arrays. Science 2004;306:630–1.CrossRef
, , , et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nature Biotechnology 2006;24:1151–61.CrossRef
. Arrays of hope. Cell 2006;127:657–9.CrossRef
, , , et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clinical Cancer Research 2007;13:3207–14.CrossRef
, , , et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. Journal of the National Cancer Institute 2006;98:1183–92.CrossRefGoogle ScholarPubMed
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genetic Medicine 2009;11:66–73.
, , , et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine 2008;359:1757–65.CrossRefGoogle ScholarPubMed
. p53 and RB: simple interesting correlates or tumor markers of critical predictive nature?Journal of Clinical Oncology 2004;22:975–7.CrossRefGoogle ScholarPubMed
, , , et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. Journal of the National Cancer Institute 1996;88:1456–66.CrossRefGoogle ScholarPubMed
, , Coates AS, Simes RJ. Molecular biomarkers to individualise treatment: assessing the evidence. Medical Journal of Australia 2009;190:631–6.Google ScholarPubMed
, , , et al. A quantitative multi-gene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. 2009 American Society of Clinical Oncology Annual Meeting, Orlando, FL;2009.
, , , et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020–9.CrossRef
. Sharing knowledge: a new frontier for public-private partnerships in medicine. Genome Medicine 2009;1:29.CrossRef
, , . Genetics. Getting closer to the whole picture. Science 2007;316:550–1.CrossRef
, , Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nature Reviews Cancer 2006;6:735–41.CrossRef
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061–8.CrossRef
The ROI for targeted therapies: a strategic perspective Washington, DC: Deloitte Center for Health Solutions; 2009.
, , , et al. A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine 2002;347:1999–2009.CrossRefGoogle ScholarPubMed
, , , et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. Journal of Clinical Oncology 2009;27:2503–8.CrossRefGoogle ScholarPubMed
, , , et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. Journal of Clinical Oncology 2007;25:1239–46.CrossRefGoogle ScholarPubMed
, , , et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute 2006;98:262–72.CrossRefGoogle ScholarPubMed
, , , et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Archives of Pathology and Laboratory Medicine 2006;130:465–73.